Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.080
-0.040 (-1.28%)
At close: Aug 21, 2026, 4:00 PM EDT
3.120
+0.040 (1.30%)
After-hours: Aug 21, 2026, 7:30 PM EDT
Pyxis Oncology Market Cap
Pyxis Oncology has a market cap or net worth of $256.9 million as of August 21, 2026. Its market cap has increased by 257.09% in one year.
Market Cap
256.90M
Enterprise Value
241.73M
1-Year Change
257.09%
Ranking
Category
Stock Price
$3.08
ChartMarket Cap Chart
Since the IPO on October 1, 2021, Pyxis Oncology's market cap has decreased from $523.75M to $256.90M, a decrease of -50.95%. That is a compound annual growth rate of -13.55%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 21, 2026 | 256.90M | 258.78% |
| Dec 31, 2025 | 71.60M | -22.81% |
| Dec 31, 2024 | 92.77M | 16.32% |
| Dec 29, 2023 | 79.75M | 70.77% |
| Dec 30, 2022 | 46.70M | -86.78% |
| Dec 31, 2021 | 353.33M | -32.54% |
| Oct 1, 2021 | 523.75M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Entrada Therapeutics | 274.03M |
| Lineage Cell Therapeutics | 273.14M |
| AC Immune | 262.49M |
| MacroGenics | 259.26M |
| Sol-Gel Technologies | 256.60M |
| Alector | 252.34M |
| Conexeu Sciences | 252.33M |
| Cellectis | 251.33M |